TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025

Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.

Sai-Hong Ignatius Ou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.